Outset Medical, Inc. — Q2 2022 Form 10-Q Summary
Business context and reporting period
Outset Medical develops and commercializes the Tablo Hemodialysis System, a connected dialysis platform designed for hospital, clinic, and home use. This unaudited Form 10-Q covers the three and six months ended June 30, 2022, with comparisons to the corresponding 2021 periods.
In May 2022, the company placed a shipment hold on Tablo for home use while the FDA reviewed a 510(k) application covering device changes. The FDA cleared the application in late July 2022, after the reporting period, and the company resumed marketing and shipping Tablo for home use.
Key financial metrics
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $25.1 million | $25.2 million | $55.6 million | $48.1 million |
| Product revenue | $19.6 million | $20.6 million | $45.3 million | $38.8 million |
| Service and other revenue | $5.4 million | $4.6 million | $10.3 million | $9.3 million |
| Gross profit | $3.8 million | $1.1 million | $8.2 million | $1.3 million |
| Gross margin | 15.1% | 4.2% | 14.8% | 2.8% |
| Loss from operations | $(43.7) million | $(29.9) million | $(80.2) million | $(59.6) million |
| Net loss | $(43.8) million | $(30.2) million | $(80.7) million | $(60.2) million |
| Net loss per share | $(0.92) | $(0.66) | $(1.69) | $(1.36) |
| Operating cash flow | Not separately provided for the quarter | Not separately provided for the quarter | $(76.9) million | $(69.5) million |
Q2 revenue was essentially flat year over year, while six-month revenue increased 16%. The Q2 gross-margin improvement reflected cost-reduction activities and product mix, partly offset by lower service margins following the planned expiration of a component of a customer lease agreement.
Financial position, debt, and liquidity
- At June 30, 2022, cash and cash equivalents were $75.5 million and short-term investments were $186.6 million, for $262.1 million of available cash and investments.
- Restricted cash was $33.3 million, primarily supporting obligations under the Silicon Valley Bank loan agreement and building leases. Total cash, cash equivalents, restricted cash, and short-term investments were $295.4 million.
- Cash, cash equivalents, and restricted cash declined to $108.8 million from $215.7 million at December 31, 2021, primarily due to operating losses and working-capital investment.
- Inventory increased to $53.7 million from $39.2 million at year-end, reflecting advance purchases to support anticipated demand and mitigate supply-chain disruptions.
- The company had a $30.0 million senior secured term loan, recorded net at $29.8 million, with $1.0 million classified as current. The loan matures in November 2025; principal payments begin in June 2023 after an interest-only period through May 2023.
- Management stated that existing cash, investments, and expected sales proceeds should fund anticipated needs for at least the next 12 months from the filing date. The company expects continued significant expenses and operating losses.
Material changes versus the prior comparable period
- Q2 product revenue decreased 5% to $19.6 million. Console revenue declined $3.6 million, primarily because staffing constraints, macroeconomic pressure, longer sales and installation cycles, and the home shipment hold delayed shipments. Consumables revenue increased $2.6 million as the installed base expanded.
- Six-month product revenue increased 17%, driven principally by a $6.8 million increase in consumables revenue and higher average selling prices.
- Service and other revenue increased 18% in Q2 and 11% for the six-month period, primarily from services associated with the larger installed base.
- Gross margin increased by 10.9 percentage points in Q2 and 12.0 percentage points for the six-month period, benefiting from manufacturing cost reductions, product mix, and scale initiatives.
- Operating expenses increased 53% in Q2 and 45% for the six-month period. Q2 research and development expense rose 68%, sales and marketing rose 76%, and general and administrative expense rose 11%, primarily due to higher headcount, infrastructure, consulting, travel, and freight costs.
- Net loss increased 45% in Q2 and 34% for the six-month period, despite improved gross profit, as operating-expense growth substantially exceeded revenue growth.
- Operating cash use increased to $76.9 million for the first six months from $69.5 million, while financing inflows fell to $4.8 million from $153.0 million because the prior-year period included $149.1 million of follow-on offering proceeds.
- Stock-based compensation increased to $12.4 million for the first six months from $9.8 million.
Guidance, outlook, commentary, and risks
- Management did not provide quantified revenue, margin, or earnings guidance in the filing. It expects revenue growth to remain moderated over the next several quarters while the company rebuilds momentum after the home shipment hold and addresses customer staffing and budget pressures.
- The company intends to expand Tablo adoption in acute-care settings, increase utilization and fleet expansion with existing customers, and scale its home-dialysis commercial, logistics, and support infrastructure.
- Management identified healthcare staffing shortages, inflation, tighter hospital budgets, increased scrutiny of capital purchases, longer sales cycles, delayed installations, and supply-chain and freight constraints as factors that negatively affected Q2 bookings and revenue.
- Supply-chain risks include dependence on critical components and transportation of Tablo cartridges from Southeast Asia. A second cartridge source in Mexico is intended to reduce freight costs and supply constraints, but management provided no assurance that disruptions will end.
- The FDA may require future 510(k) clearances for product modifications. The FDA placed a prior Section 522 post-market surveillance study requirement on hold in July 2022, but it remains uncertain whether a new or extended study will be required for the current Tablo version.
- On July 8, 2022, a purported stockholder class action lawsuit was filed against the company and certain current and former officers. The complaint alleges misleading statements regarding Tablo’s home-use regulatory studies and home-market prospects. The case was at an early stage, and the company could not estimate any potential loss or range of losses.
- The company continues to incur losses and negative operating cash flow and may need additional equity or debt financing. Additional equity could dilute existing holders, while additional debt could impose restrictive covenants.
- Available-for-sale securities had $955,000 of unrealized losses at June 30, 2022. Management attributed the losses to interest-rate and market-spread changes rather than issuer credit deterioration and recorded no other-than-temporary impairment.
Important facts for investors to verify
- Whether the late-July 2022 FDA clearance restored home-market bookings, shipments, and pipeline momentum.
- Whether customer staffing shortages, inflation, hospital budget pressure, and longer installation cycles continue to suppress console revenue and bookings.
- Whether improved gross margins are sustainable as product mix, freight costs, service costs, and manufacturing scale change.
- The pace of consumables growth and utilization expansion relative to the installed Tablo console base.
- Cash burn, inventory levels, available liquidity, and the timing of the $1.0 million current term-loan repayment and later principal amortization.
- Whether the FDA requires a new or extended Section 522 post-market surveillance study and whether additional product changes, shipment holds, recalls, or labeling actions result.
- The scope, potential cost, and reputational impact of the stockholder litigation, noting that the filing does not provide a clear estimate of potential losses.
- The company’s ability to achieve operating leverage as research and development and sales and marketing investments continue to grow.